Nicholas Piramal India Limited buys Pharmaceuticals business of Healthline Private Limited, Bangalore.

Nicholas Piramal reports Q3 FY2008 results;

Dr. L H Hiranandani Hospital outsources its Radiology Department to Nicholas Piramal (I) Ltd subsidiary Wellspring.

Nicholas Piramal enters into a Joint Venture with ARKRAY, Inc. Japan, for marketing Diagnostic products.

Nicholas Piramal Secures Product Patent from US Patent & Trademark Office for its Cyclin-Dependent Kinase (CDK) inhibitors

Nicholas Piramal Announces Drug Discovery and Development Agreement with Merck & Co., Inc.

Nicholas Piramal reports Q2 FY2008 results;

Nicholas Piramal to de-merge its New Chemical Entity (NCE) Research and Development unit into an independent company

Nicholas Piramal India Limited’s reports Q1 FY2008 results;

Nicholas Piramal India Limited’s IND-P276- a new drug discovery from Mumbai, India has been approved by USFDA

Nicholas Piramal reports Q4 FY2007 results

Formulation capabilities to leverage NPIL Pharma growth

Nicholas Piramal reports Q3 FY2007 results

Nicholas Piramal announces Drug Development Agreement with Eli Lilly and Company.

Nicholas Piramal's Wellspring acquires majority stake in Jankharia Imaging to become India's First Corporate to enter into High-End Health Imaging Services.

FDA MAHARASHTRA clears unconditionally, Vitamin A solution manufactured by Nicholas Piramal

BioSyntech signs scientific collaboration agreement with Nicholas Piramal

Nicholas Piramal signs two Platform Technology agreements with Morvus Technology Limited, UK, for R&D programs in Diabetes, Rheumatoid Arthritis and Oncology.

Nicholas Piramal reports Q2 FY2007 results

Nicholas Piramal announces acquisition of balance 51% equity stake in Boots Piramal Healthcare Private Limited

Information: NPIL Opens Shanghai Office

Nicholas Piramal wins The 2006 International Spirit at Work Award

Nicholas Piramal reports Q1 FY2007 results; Total Revenues up 31.2% to Rs. 5.2 billion, Net Profit up by 7.3% to Rs. 538.6 million.

Dr.Swati Piramal is awarded French Chevalier de l'Ordre National du Mérite

Nicholas Piramal India Limited, makes BOARD changes

Acquisition of Pfizer's Morpeth UK Facility - Completion of Transaction

Nicholas Piramal signs agreement to acquire Pfizer’s Morpeth, UK Facility with potential outsourcing revenues exceeding US$350 million

Nicholas Piramal India Limited contemplating acquisitions

Nicholas Piramal reports audited Q4 FY2006 results; Net sales up 57.3% to Rs 3.3 billion, Net profit Rs. 375.9 million.

Nicholas Piramal reports audited Q3 FY2006 results; Sales up 9.2% to
Rs. 3.5 billion, Net Profit (pre-exceptional items) down 31.6% to Rs. 238.7 million

Nicholas Piramal India Limited announces Agreement with Pfizer International LLC

Nicholas Piramal India Limited announces 10-year Manufacturing and Supply Agreement

Nicholas Piramal India Limited - Announcement:
Custom Manufacturing Group Head

Nicholas Piramal acquires Avecia Pharmaceuticals, UK for a consideration of GBP 9.5 million

AstraZeneca and Nicholas Piramal announce Development and Know-how Agreement

Nicholas Piramal reports audited Q2 FY2006 results; Sales down 2.0% to Rs. 3.5 billion, Net Profit up by 0.9% to Rs. 549.0 million

NPIL Q1 FY2006 Results

Nicholas Piramal India Limited Invests 17% equity in Canadian Biotech Reserach Company - Biosyntech, Inc

Press statement from Chairman on recent news report

Nicholas Piramal reports HY-FY05 results; Sales from continuing operations up 16.4%, Profit after tax up 34.2%

Wellquest becomes the first Indian CRO to receive Statement of GCP Compliance from UK-MHRA

Nicholas Piramal Seals Product In-Licensing Agreement with Ethypharm, France for the Indian Market

Nicholas Piramal Seals an In-Licensing Agreement with Genzyme Corporation for the Indian Market.

Nicholas Piramal acquires India rights for Dobutrex from Eli Lily & Co.

Information Memorandum - Kojam Fininvest Limited
The above file requires Adobe Acrobat Reader to view

Pithampur plant gets INVIMA-Columbia approval

Nicholas Piramal’s operating profit surpasses Rs. 2 billion; 
Export sales cross Rs1 billion; Consolidated EPS exceeds Rs 50 for FY 2003-04

Nicholas Piramal registers 76.1% growth in PAT 19.3% growth in Sales in Q3 FY04.

Nicholas Piramal merges Hyderabad based Canere Actives and Fine Chemicals Pvt Ltd.

Nicholas Piramal India Limited and Advanced Medical Optics Inc. sign agreement for supply of products.

Nicholas Piramal enters into alliance with Biogen Idec of USA
Launches Avonex^®, the leading global therapy for Multiple Sclerosis
Rollout Curosurf^®, a product of Chiese, Italy

NPIL's Wellquest CRO Audit by ANVISA, Brazil

Nicholas Piramal’s registers 22.3% growth in sales for Q2 FY04
Net Sales of Rs. 3110.0 million; Profits grew faster than sales
Operating Profits up by 26.2% and Net Profits up by 82.4%

Nicholas Piramal registers strong growth for Q1 FY04, Net Sales up 18.2%
to download presentation click here

Nicholas Piramal registers record results for 2002-03, Sales up 20%t

Nicholas Piramal moves to enhance shareholder value
to download presentation click here

Nicholas Piramal Q3 Net at Rs 21 crore

Nicholas Piramal to market Minrad's new generation inhalation anesthetics in 10 countries